Kerri Fitzgerald

DocwireNews

The U.S. Food and Drug Administration approved Sevenfact (coagulation factor VIIa [recombinant]-jncw) for the treatment of adults and adolescents (12 years and older) with <a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/estimating-intracranial-hemorrhage-burden-with-claims-data-for-hemophilia-a/">hemophilia</a> A and B with inhibitors.The active ingredient in coagulation factor VIIa (recombinant)-jncw is a recombinant analog of human FVII, which is expressed in the mammary gland of genetically engineered rabbits and secreted into the rabbits&rsquo; milk. During purification and processing of the milk, FVII is converted into activated FVII.The safety and efficacy of this treatment were assessed in a clinical trial that included 27 patients with <a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/paradigm-shift-for-hereditary-hemophilia-towards-precision-medicine/">hemophilia</a> A or B with inhibitors. In this cohort, there were 465 mild or moderate and three severe bleeding episodes requiring treatment. The study assessed the efficacy of treatment 12 hours after the initial dose was given; there were two doses studied: low, 75 mcg/kg; and high, 225 mcg/kg. A previous study evaluated the safety and pharmacokinetics of three escalating doses of coagulation factor VIIa (recombinant)-jncw in 15 patients with severe hemophilia A or B with or without inhibitors and found the two doses, 75mcg/kg and 225 mcg/kg, to be acceptable.<h2>Bleeding episodes successfully treated</h2>The proportion of mild or moderate bleeding episodes successfully controlled (defined as requiring no further treatment for the bleeding episode, no administration of blood products, and no increase in pain beyond 12 hours from initial dose) with both doses was approximately 86%. The three severe bleeding episodes were treated successfully with the higher dose.The most common adverse events associated with coagulation factor VIIa (recombinant)-jncw are headache, dizziness, infusion site discomfort, infusion-related reaction, infusion site hematoma, and fever. Patients with hemophilia A or B with inhibitors who have other risk factors for thrombosis may be at increased risk of serious arterial and venous thrombotic events.&nbsp;This product is contraindicated in patients with a known allergy or hypersensitivity to rabbits or rabbit proteins.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

FDA Approves New Treatment for Hemophilia A, B with Inhibitors

Hemophilia

The U.S. Food and Drug Administration approved Sevenfact (coagulation factor VIIa [recombinant]-jncw) for the treatment of adults and adolescents (12 years and older) with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe